Secondary hypertension — endocrine and renovascular screening
secondary HTN · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Targeted evaluation for identifiable causes of hypertension, especially primary aldosteronism, renovascular disease, renal parenchymal disease, phaeochromocytoma and Cushing syndrome. Indicated in resistant, young-onset, severe or features-suggestive hypertension to enable curative or specific therapy.
Red flags
- Malignant hypertension with end-organ damage
- Flash pulmonary oedema (bilateral renal artery stenosis)
- Paroxysmal headache/palpitations/sweating (phaeochromocytoma)
- AKI after starting ACEi/ARB (renovascular)
- Severe spontaneous or diuretic-induced hypokalaemia (aldosteronism)
Assessment
Differential diagnosis
- Primary aldosteronism
- Renovascular hypertension (atherosclerotic or fibromuscular)
- Renal parenchymal disease (CKD)
- Phaeochromocytoma/paraganglioma
- Cushing syndrome
- Obstructive sleep apnoea / thyroid / coarctation
Investigations
- Aldosterone:renin ratio (primary aldosteronism) — withhold interfering drugs where possible
- U&E (hypokalaemia), eGFR, urine ACR, urinalysis
- Renal duplex ultrasound / CT or MR angiography (renovascular)
- Plasma/urine metanephrines (phaeochromocytoma)
- Overnight dexamethasone suppression / late-night salivary cortisol (Cushing)
- TFTs, sleep study if OSA suspected
Management
- Identify who to screen: resistant hypertension, young onset (<40), severe/malignant, hypokalaemia, incidental adrenal mass or suggestive features
- Confirm sustained hypertension with out-of-office readings and review adherence/drug causes
- Measure aldosterone:renin ratio for primary aldosteronism (the commonest secondary cause), accounting for interfering antihypertensives
- If ARR positive, arrange confirmatory testing and adrenal CT +/- adrenal vein sampling via endocrinology
- Screen for renovascular disease with renal duplex or CT/MR angiography when clinical clues exist (flash pulmonary oedema, bruit, AKI on ACEi, FMD in young women)
- Exclude renal parenchymal disease with renal function, urinalysis, ACR and ultrasound
- Test for phaeochromocytoma (metanephrines) if paroxysmal symptoms, labile BP or adrenal mass
- Screen for Cushing syndrome if cushingoid features or resistant hypertension with diabetes
- Consider OSA, thyroid disease and coarctation per clinical picture
- Treat the specific cause: MRA or adrenalectomy for aldosteronism, revascularisation selectively for renovascular disease, surgery for phaeochromocytoma/Cushing
- Optimise BP control pending definitive treatment
- Refer to the relevant specialist (endocrinology, vascular, nephrology) for confirmatory testing and management
Drugs & doses
Spironolactone 25-50 mg PO daily OR eplerenone 25-50 mg PO twice daily (primary aldosteronism medical therapy)
Amlodipine 5-10 mg PO daily and other agents to control BP during work-up
Phenoxybenzamine 10 mg PO twice daily, uptitrated (alpha-blockade before phaeochromocytoma surgery)
Doxazosin MR 4-8 mg PO daily (add-on BP control)
Disposition
Outpatient work-up with endocrinology/hypertension specialist; vascular or nephrology referral for renovascular disease. Surgery for phaeochromocytoma, Cushing or aldosterone-producing adenoma.
Complications & pitfalls
- Cardiovascular and renal damage from uncontrolled hypertension
- Hypertensive crisis in undiagnosed phaeochromocytoma
- Progressive renovascular ischaemic nephropathy
- Hypokalaemia from aldosteronism
- Missed curable cause
Exam pearls
- Primary aldosteronism is far more common than historically thought — screen liberally in resistant/hypokalaemic HTN
- Do not start alpha-blockade without beta cover timing in phaeochromocytoma, and never beta-block first (unopposed alpha)
- AKI on starting an ACE inhibitor suggests bilateral renal artery stenosis
- Fibromuscular dysplasia causes renovascular HTN in young women and is treatable by angioplasty
- Account for interfering drugs when interpreting the aldosterone:renin ratio
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.